Filing Details
- Accession Number:
- 0001209191-21-002831
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-08 19:28:46
- Reporting Period:
- 2021-01-06
- Accepted Time:
- 2021-01-08 19:28:46
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1070494 | Acadia Pharmaceuticals Inc | ACAD | Pharmaceutical Preparations (2834) | 061376651 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1432545 | R. Srdjan Stankovic | C/O Acadia Pharmaceuticals Inc. 12830 El Camino Real, Suite 400 San Diego CA 92130 | President | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-01-06 | 5,444 | $0.00 | 21,972 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-01-06 | 1,725 | $53.34 | 20,247 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-01-07 | 61,619 | $35.80 | 81,866 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-01-07 | 61,619 | $55.12 | 20,247 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-01-08 | 13,381 | $35.80 | 33,628 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2021-01-08 | 12,864 | $21.28 | 46,492 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2021-01-08 | 3,488 | $18.12 | 49,980 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-01-08 | 29,733 | $55.22 | 20,247 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Units | Disposition | 2021-01-06 | 5,444 | $0.00 | 5,444 | $0.00 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-01-06 | 61,619 | $0.00 | 61,619 | $35.80 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-01-08 | 13,381 | $0.00 | 13,381 | $35.80 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-01-08 | 12,864 | $0.00 | 12,864 | $21.28 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-01-08 | 3,488 | $0.00 | 3,488 | $18.12 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
16,333 | No | 4 | M | Direct | ||
69,631 | 2027-09-06 | No | 4 | M | Direct | |
56,250 | 2027-09-06 | No | 4 | M | Direct | |
22,761 | 2028-10-14 | No | 4 | M | Direct | |
90,262 | 2028-11-18 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2020.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.77 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- The restricted stock units vest in four equal annual installments beginning January 6, 2021.
- 25% of the shares subject to the Stock Option vested and became exercisable on September 7, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
- 25% of the shares subject to the Stock Option vested and became exercisable on October 15, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
- 25% of the shares subject to the Stock Option vested and became exercisable on November 19, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.